Roche has announced additional encouraging results of a phase II study with lampalizumab to treat patients with geographic atrophy (GA). The MAHALO study data was presented during the Retina subspeciality day at AAO 2013 in New Orleans, Louisiana, USA.
2013 has been an important year in retina therapy, with increased information released on nutritional supplements for AMD patients, widened indications for anti-VEGFs and the approval of treatment for symptomatic vitreomacular adhesion.
Patients who receive intravitreal ranibizumab for treatment of diabetic macular oedema over a 3-year period achieved rapid improvements in vision and oedema.
In this article, the authors review the various corticosteroid options and attempt to determine their place in the therapeutic regimen.
Ophthalmologists from 76 countries discussed the latest findings in diagnostics and therapy, and also issues of promoting the next generation of young ophthalmologists.
Progranulin, a protein found in fat-derived stem cells, may reverse and perhaps prevent age-related, light-induced retinal damage, according to results from a study done in a mouse model by researchers from Gifu Pharmaceutical University and Gifu University, Japan.
One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in the November 2013 issue of Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years? duration of diabetes, the presence of diabetic retinopathy was almost universal.
Oral pazopanib - in a dose of 15 mg/d - is well tolerated and may improve mean best-corrected visual acuity (BCVA), central retinal lesion thickness and central retinal thickness in as little as 1 month of treatment in some patients with age-related macular degeneration (AMD), according to recent study results.
In this article, Dr Vinekar describes the Karnataka Internet Assisted Diagnosis of Retinopathy of Prematurity (KIDROP) programme and how this is changing the landscape of eye screening in India.
The National Institute for Health and Care Excellence (NICE) has recommended ocriplasmin (Jetrea) as a clinically effective and cost-effective treatment option for patients suffering from vitreomacular traction, including that associated with macular hole of ? 400 ?m when an epiretinal membrane is absent, or adults with vitreomacular traction and severe symptoms, when an epiretinal membrane and macular hole are both absent.
Novartis has launched a fully interactive Facebook app, ?Retina App,? which simulates retinal disease by illustrating the user?s journey with a highly realistic view of the possible impact of vision loss on their daily lives.
Largest retrospective review of patients with vitreomacular adhesion (VMA) and vitreomacular traction (VMT) confirms that early treatment initiation may stop disease progression and lead to better visual function outcome.
KalVista Pharmaceuticals is joining a group of academic and industry researchers to undertake a project known as “Drug Discovery and Development of Novel Eye Therapeutics†(3D-NET).
In its final appraisal determination, the United Kingdom's National Institute for Health and Care Excellence (NICE) has recommended funding for Iluvien for the treatment of pseudophakic eyes in chronic diabetic macular edema (DME) patients that are insufficiently responsive to available therapies.
Recurrent retinal detachments in children can develop months to years after the initial corrective surgery, making careful monitoring of patients imperative to identifying late re-detachments.
In this article, the authors discuss preventative efforts related to retinal diseases that are made by ophthalmologists to avoid infections and how mounting data seems to be pointing at the discontinuation of peri-injection topical antibiotic drops.
This article provides a brief overview of the outcomes of a webex meeting hosted by Novartis at SOE 2013 in Copenhagen, Denmark.
PPV has been a major advancement in the treatment of retinal diseases, however, little is known about its effect on oxygen metabolism in retinal vessels. In this article, Dr Sin reveals the results of his pilot study examining the effect of PPV on the oxygen saturations in retinal vessels.
During the advent of surgical approaches for retinal detachment repair, one of the most challenging cases a retinal surgeon may come across was a giant retinal tear. This article summarizes the history of GRT management and discusses current trends in surgical management.
In this article, Mr Dogramaci highlights a recent study in which he and his colleagues examined the characteristics of RRD and the relationship these characteristics have on visual outcome.
Professor Stef?nsson reveals the results of a comparative study demonstrating that observation of metabolic processes is possible enabling insight into the pathophysiology of disease.
The Transparency Commission of the French National Health Authority has issued a positive opinion for the reimbursement and hospital listing of Iluvien.
Oraya Therapeutics has announced that Oraya Therapy Stereotactic Radiotherapy for the treatment of wet AMD is now available at Optegra Manchester Eye Hospital.
Jetrea, developed by ThromboGenics, offers ?major added value? for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).
A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.
